Healthcare: This Drug Pricing Scheme Cou...

We're moving over to a new show! Here's a sneak peek of what to expect when Motley Fool Money goes daily on January 5, 2022. Subscribe here on Spotify Subscribe here on Apple Podcasts 

Nick, Emily, Jason, and Dylan get together to talk through the companies they've learned the most from, the stocks they've sold recently (and why!) and also where you can catch all of them with The Motley Fool's new audio offering in 2022. Stocks: MELI, SHOP, GME, BBY Check out m ... Show More

In this last iteration of Industry Focus Consumer Goods (don’t worry - we’re just moving to Motley Fool Money!), Emily Flippen and Asit Sharma revisit their 2021 consumer goods basket as well as reflect on lessons learned from investing in the industry at large. Stocks: Grocery O ... Show More

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More

<p>Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their s ... Show More

Endo Pharmaceuticals and its attorneys at Arnold & Porter are facing accusations of serious discovery misconduct during opioid litigation across the country, threatening the company with huge liability and the lawyers with reputational damage. On this week’s show, we break down t ... Show More

Why is it so hard to find a cure for Alzheimer’s? A simple answer is that the brain and its disorders are complicated. But as today’s guest, Charles Piller, writes, there’s another, more sinister factor at play. His new book, 'Doctored,' traces an incredible, true story of fraud, ... Show More

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More

Bloomberg News Health Reporter Madison Muller discusses how the drug Ozempic could cut demand for big-money drugs targeting a wide range of maladies, even Alzheimer’s. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.See omnystudio.com/listener for privacy information ... Show More